Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:06am, Wednesday, 18'th Dec 2024
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys
08:10am, Wednesday, 18'th Dec 2024
In November, I invested $1,400 primarily in Business Development Companies, boosting my yearly dividend income by $148, with a YTD total exceeding $1,400. My portfolio achieved all-time highs, driven
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
08:00am, Wednesday, 18'th Dec 2024
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo; Topic is Pharmacokinetics of AL001.
Barclays fact-checked Trump comments on pharmacy benefit managers
01:40pm, Tuesday, 17'th Dec 2024
Barclays analyst Andrew Mok said that while the existential risk to pharmacy benefit managers is low, President-elect Trump's comments yesterday point to additional headline risk and greater support f
4 Big Drug Stocks That May Continue to Outperform in 2025
11:06am, Tuesday, 17'th Dec 2024
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
08:00am, Tuesday, 17'th Dec 2024
AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock. The post AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth.
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
06:51pm, Monday, 16'th Dec 2024
In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.
Why Investors Should Watch AbbVie Inc (ABBV)
04:39pm, Monday, 16'th Dec 2024
AbbVie Inc is a global biopharmaceutical company that specializes in the discovery, development, manufacturing, and marketing of advanced medicines. AbbVie focuses primarily on immunology, oncology,
AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors
03:28pm, Monday, 16'th Dec 2024
AbbVie offers a compelling investment opportunity after a recent price drop, combining dividend income, value, and growth potential driven by a strong drug portfolio and pipeline. Robust growth in imm
AbbVie Enters Oversold Territory
11:37am, Monday, 16'th Dec 2024
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?
11:21am, Monday, 16'th Dec 2024
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
10:46am, Monday, 16'th Dec 2024
AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
05:35am, Sunday, 15'th Dec 2024
Investing in a company to hold it forever is a simple idea, but it's not easy. Most companies can't maintain competitive advantages forever.
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
11:54pm, Friday, 13'th Dec 2024
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
09:15am, Friday, 13'th Dec 2024
Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoim
